Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Vaccine

• Publication date

  2009-12-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2009.10.031PMID 20006142
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Use of Cumulative Incidence of Novel Influenza A/H1N1 in Foreign Travelers to Estimate Lower Bounds on Cumulative Incidence in Mexico

  2009cited by this paper
• Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges

  2009cited by this paper
• Emulsion-based adjuvants for influenza vaccines

  2009cited by this paper
• Current status and progress of prepandemic and pandemic influenza vaccine development

  2009cited by this paper
• Prioritization of Pandemic Influenza Vaccine: Rationale and Strategy for Decision Making

  2009cited by this paper
• Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

  2009cited by this paper
• Trial of Influenza A (H1N1) 2009 Monovalent MF59-Adjuvanted Vaccine — Preliminary Report

  2009cited by this paper
• Response after One Dose of a Monovalent Influenza A (H1N1) 2009 Vaccine — Preliminary Report

  2009cited by this paper
• Trivalent inactivated subunit influenza vaccine Influvac: 25-Year experience of safety and immunogenicity.

  2009cited by this paper
• Response to a monovalent 2009 influenza A (H1N1) vaccine.

  2009cited by this paper
• Influenza vaccine supply: building long-term sustainability.

  2008cited by this paper
• Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial.

  2008cited by this paper
• Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

  2008cited by this paper
• Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch.

  2008cited by this paper
• Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.

  2008cited by this paper
• An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

  2008cited by this paper
• A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults.

  2007cited by this paper
• Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.

  2007cited by this paper
• Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch

  2007cited by this paper
• Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

  2007cited by this paper
• The adjuvant patch : A universal dose sparing approach for pandemic and conventional vaccines

  2007cited by this paper
• Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

  2006cited by this paper
• Vaccines for seasonal and pandemic influenza.

  2006cited by this paper
• Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

  2006cited by this paper
• Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

  2006cited by this paper
• Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch.

  2005cited by this paper
• Immunostimulant Patch Enhances Immune Responses to Influenza Virus Vaccine in Aged Mice

  2004cited by this paper
• Immunostimulant Patch Containing Heat-Labile Enterotoxin from Escherichia coli Enhances Immune Responses to Injected Influenza Virus Vaccine through Activation of Skin Dendritic Cells

  2003cited by this paper
• Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts.

  1999cited by this paper
• Live influenza A/Victoria/75 (H3N2) virus vaccines: reactogenicity, immunogenicity, and protection against wild-type virus challenge

  1982cited by this paper
• Protection of infants from infection with influenza A virus by transplacentally acquired antibody.

  1980cited by this paper
• Efficacy of purified influenza subunit vaccines and relation to the major antigenic determinants on the hemagglutinin molecule.

  1979cited by this paper
• Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man.

  1971cited by this paper

• Influenza vaccines: Past, present, and future

  2021cites this paper
• Co-administered Tag-Less Toxoid Fusion 3xSTaN12S-mnLTR192G/L211A and CFA/I/II/IV MEFA (Multiepitope Fusion Antigen) Induce Neutralizing Antibodies to 7 Adhesins (CFA/I, CS1-CS6) and Both Enterotoxins (LT, STa) of Enterotoxigenic Escherichia coli (ETEC)

  2018cites this paper
• Adjuvanted influenza vaccines

  2018cites this paper
• Gene Transfer to the Skin by Physical Methods of Delivery

  2017cites this paper
• Toxin-Based Mucosal Adjuvants

  2017cites this paper
• Immunogenicity and Safety of Pandemic Influenza H5N1 Vaccines in Healthy Adults through Meta-Analysis

  2016cites this paper
• Nanoengineering of vaccines using natural polysaccharides

  2015cites this paper
• Current and next generation influenza vaccines: Formulation and production strategies.

  2015cites this paper
• Parenteral Adjuvant Effects of an Enterotoxigenic Escherichia coli Natural Heat-Labile Toxin Variant

  2014cites this paper
• Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines.

  2014cites this paper
• Vaccine technologies against avian influenza: current approaches and new directions.

  2014cites this paper
• Influenza vaccination in HIV-positive subjects: latest evidence and future perspective

  2013influential citation
• Adjuvanted influenza vaccines

  2013cites this paper
• Synthetic nanoparticle-based vaccines against respiratory pathogens

  2013cites this paper
• Transcutaneous immunization with Intercell's vaccine delivery system.

  2012cites this paper
• Transcutaneous Immunization via Vaccine Patch Delivery System

  2012cites this paper
• Escherichia coli Heat-Labile Enterotoxin Promotes Protective Th17 Responses against Infection by Driving Innate IL-1 and IL-23 Production

  2011cites this paper
• Vaccine effectiveness in older individuals: what has been learned from the influenza-vaccine experience.

  2011cites this paper
• Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations

  2011cites this paper
• Challenges in improving influenza vaccine protection in the elderly

  2011cites this paper
• Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.

  2011cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  2010cites this paper
• AB Toxins: A Paradigm Switch from Deadly to Desirable

  2010cites this paper
• Pediatric Vaccines on the Horizon

  2010cites this paper
• Current and next generation influenza vaccines: Formulation and production strategies

  year unknowncites this paper